

DMD-AR-2024-001867

Supplemental Data

Drug Metabolism and Disposition

CYP and non-CYP drug metabolizing enzyme families exhibit differential sensitivities towards pro-inflammatory cytokine modulation

Laura M. de Jong, Chandan Harpal, Dirk-Jan van den Berg, Menno Hoekstra, Nienke J.

Peter, Robert Rissmann, Jesse J. Swen and Martijn L. Manson

Supplemental materials and methods: LC-MS/MS method to quantify FMO3 and UGT2B7 activity

Supplemental Table 3. MRM parameters and retention time for the quantified analytes by the LC-MS/MS method.

Analyte	Q1 mass (Da)	Q3 mass (Da)	Retention time (min)	DP (V)	CE (V)
Benzydamine N-oxide	326.2	102.1	4.5	16	9
Benzydamine N-oxide-d ₆	332.2	108.2	4.5	16	8
Morphine-3-glucuronide	462.1	152.9, 201.0, 286.113	4.4	6	62, 48 and 24
Morphine-3-glucuronide-d ₃	465.2	152.9, 201.0, 289.074	4.4	6	62, 48 and 24